MannKind Corp has produced insulin that can be inhaled by adult diabetics with Type 1 and Type 2 diabetes. This new, powdered insulin has proved to be more effective than injected and oral treatments and has the ability to turn MannKind Corp into a multi-billion dollar company. The product, referred to as Afrezza, is an inhaler about the size of a whistle. With the number of diabetics projected to reach nearly half a billion by 2030, MannKind’s new product has great potential to capture worldwide attention. According to a July report by Transparency Market Research, “the global insulin market is expected to reach $32 billion in 2018.” The U.S. Food and Drug Administration originally rejected the product in 2011, asking the company to produce two more clinical trials. The company said it anticipates submitting data to the FDA in December. MannKind is also eager to release two potential cancer treatments currently in development.
Click here to read more